Basis of PD1/PD-L1 Therapies

Upregulation of long noncoding RNA SNHG20 promotes cell growth and metastasis in esophageal squamous cell carcinoma via modulating ATM-JAK-PD-L1 pathway

(2019) Chunrong Zhang et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?

(2019) Martin Reck et al.   Future Oncology

Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory

(2019) Mauro Poggio et al.   CELL

MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells

(2019) Thijs S Stutvoet et al.   JOURNAL OF PATHOLOGY

Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-κB, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma

(2019) Christelle Vincent-Fabert et al.   Cell Communication and Signaling

Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils

(2019) Anquan Shang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

(2019) Akintunde Akinleye et al.   Journal of Hematology & Oncology

Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response

(2019) Alexander Haragan et al.   LUNG CANCER

LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint

(2019) Lina Zhao et al.   Cell Death & Disease

PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition

(2019) Yilun Wu et al.   Frontiers in Immunology

Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities

(2019) Antonio Santaniello et al.   Cancers

Association of PD‐L1 expression status with the efficacy of PD‐1/PD‐L1 inhibitors and overall survival in solid tumours: A systematic review and meta‐analysis

(2019) Xi Liu et al.   INTERNATIONAL JOURNAL OF CANCER

The role of exosomal PD-L1 in tumor progression and immunotherapy

(2019) Feiting Xie et al.   Molecular Cancer

Efficacy of Cancer Immunotherapy: An Umbrella Review of Meta-analyses of Randomized Controlled Trials

(2019) Kim et al.   Cancers

The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis

(2019) Yongfeng Wu et al.   Frontiers in Oncology

Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC

(2018) MARIA BASSANELLI et al.   ANTICANCER RESEARCH

Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1

(2018) Chia-Wei Li et al.   CANCER CELL

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

(2018) Matthew D. Hellmann et al.   CANCER CELL

Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression

(2018) Wen-Hao Yang et al.   CANCER RESEARCH

JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer

(2018) Meixuan Chen et al.   Clinical Breast Cancer

Regulation and Function of the PD-L1 Checkpoint

(2018) Chong Sun et al.   IMMUNITY

IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells

(2018) Wei Xiao et al.   JOURNAL OF IMMUNOLOGY

Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations

(2018) Ioannis Zerdes et al.   ONCOGENE

Epigenetic regulators of programmed death-ligand 1 expression in human cancers

(2018) Sachin Kumar et al.   Translational Research

PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma

(2018) A. Asgarova et al.   OncoImmunology

Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors

(2018) Aaron M. Goodman et al.   JAMA Oncology

PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET exon 14 Altered Lung Cancers

(2018) J K Sabari et al.   ANNALS OF ONCOLOGY

PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy

(2018) Fatemeh K. Dermani et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Effect of anthracycline and taxane on the expression of programmed cell death ligand-1 and galectin-9 in triple-negative breast cancer

(2018) Hye Kyoung Yoon et al.   PATHOLOGY RESEARCH AND PRACTICE

Association of PD-L1 gene rs4143815 C>G polymorphism and human cancer susceptibility: A systematic review and meta-analysis

(2018) Ju Zou et al.   PATHOLOGY RESEARCH AND PRACTICE

PD-1 and cancer: molecular mechanisms and polymorphisms

(2017) Arash Salmaninejad et al.   IMMUNOGENETICS

The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint

(2017) Qingshui Wang et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Immune Modulatory microRNAs Involved in Tumor Attack and Tumor Immune Escape

(2017) Stefan B. Eichmüller et al.   JNCI-Journal of the National Cancer Institute

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

(2017) Fred R. Hirsch et al.   Journal of Thoracic Oncology

PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma

(2017) V Atsaves et al.   LEUKEMIA

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators

(2017) Riccardo Mezzadra et al.   NATURE

Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance

(2017) Jinfang Zhang et al.   NATURE

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity

(2017) Marian L. Burr et al.   NATURE

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

(2017) Mizuki Nishino et al.   Nature Reviews Clinical Oncology

Tumor Mutational Burden and Response Rate to PD-1 Inhibition

(2017) Mark Yarchoan et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective

(2017) Palanisamy Nallasamy et al.   SEMINARS IN CANCER BIOLOGY

MYC: Master Regulator of Immune Privilege

(2017) Stephanie C. Casey et al.   TRENDS IN IMMUNOLOGY

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

(2017) Moshe Sade-Feldman et al.   Nature Communications

Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinoma

(2017) Hyein Ahn et al.   Oncotarget

Immune Modulatory microRNAs Involved in Tumor Attack and Tumor Immune Escape

(2017) Stefan B. Eichmüller et al.   JNCI-Journal of the National Cancer Institute

Identifying Regulatory Posttranslational Modifications of PD-L1: A Focus on Monoubiquitinaton

(2017) Henrick Horita et al.   NEOPLASIA

PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma

(2017) Jan Budczies et al.   OncoImmunology

A polymorphism in the promoter region of PD-L1 serves as a binding-site for SP1 and is associated with PD-L1 overexpression and increased occurrence of gastric cancer

(2016) Li-Hua Tao et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer

(2016) Julie George et al.   CLINICAL CANCER RESEARCH

PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma

(2016) J. Madore et al.   CLINICAL CANCER RESEARCH

Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival

(2016) Jan Budczies et al.   GENES CHROMOSOMES & CANCER

Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors

(2016) Jonathan M. Pitt et al.   IMMUNITY

Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels

(2016) Zsofia K. Stadler et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non–Small Cell Lung Cancer

(2016) Seiichi Ikeda et al.   Journal of Thoracic Oncology

Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers

(2016) Keisuke Kataoka et al.   NATURE

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

(2016) Chia-Wei Li et al.   Nature Communications

TGF 1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer

(2016) B. V. Park et al.   Cancer Discovery

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

(2016) Daniel Sanghoon Shin et al.   Cancer Discovery

CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity

(2016) Melanie Straub et al.   Oncotarget

Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer

(2016) Yusuke Inoue et al.   Oncotarget

Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants

(2016) Subrata Chowdhury et al.   Oncotarget

The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation

(2016) Kankana Bardhan et al.   Frontiers in Immunology

Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies

(2016) B. Seliger   HLA

Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva

(2016) Brooke E. Howitt et al.   JAMA Oncology

Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer

(2016) Jin S. Im et al.   PLoS One

EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB

(2015) Kailong Lin et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells

(2015) Z. Sun et al.   CANCER RESEARCH

Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer

(2015) Kristin J. Lastwika et al.   CANCER RESEARCH

Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer

(2015) K. Ota et al.   CLINICAL CANCER RESEARCH

Programmed Death-1 Controls T Cell Survival by Regulating Oxidative Metabolism

(2015) Victor Tkachev et al.   JOURNAL OF IMMUNOLOGY

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

(2015) S. P. Patel et al.   MOLECULAR CANCER THERAPEUTICS

The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer

(2015) Yu Fujita et al.   MOLECULAR THERAPY

Combination cancer immunotherapy and new immunomodulatory targets

(2015) Kathleen M. Mahoney et al.   NATURE REVIEWS DRUG DISCOVERY

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation

(2015) Nuala A. O'Leary et al.   NUCLEIC ACIDS RESEARCH

Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1

(2015) Krzysztof M. Zak et al.   STRUCTURE

PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation

(2015) Nikolaos Patsoukis et al.   Nature Communications

Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer

(2015) Michael T. Barrett et al.   Oncotarget

Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB

(2015) Kavitha Gowrishankar et al.   PLoS One

Alterations of immune response of non-small cell lung cancer with Azacytidine

(2015) John Wrangle et al.   Oncotarget

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

(2014) K. Azuma et al.   ANNALS OF ONCOLOGY

Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma

(2014) David D. W. Twa et al.   BLOOD

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

(2013) H Yang et al.   LEUKEMIA

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

(2013) E. A. Akbay et al.   Cancer Discovery

MYC on the Path to Cancer

(2012) Chi V. Dang   CELL

Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation

(2012) N. Patsoukis et al.   Science Signaling

B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma

(2012) Dong Hua   WORLD JOURNAL OF GASTROENTEROLOGY

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

A frequent somatic mutation in CD274 3′-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding

(2011) Weipeng Wang et al.   HUMAN MUTATION

Soluble B7-H1: Differences in production between dendritic cells and T cells

(2011) Xavier Frigola et al.   IMMUNOLOGY LETTERS

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

(2008) M. Marzec et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA